Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Reviva Pharmaceuticals Holdings ( (RVPH) ) has issued an update.
On September 26, 2025, Reviva Pharmaceuticals Holdings, Inc. announced an amendment to its Bylaws, reducing the quorum requirement for stockholder meetings from a majority to one-third of the voting power. This change is aimed at facilitating the transaction of business by making it easier to achieve a quorum at meetings, potentially impacting shareholder engagement and decision-making processes.
The most recent analyst rating on (RVPH) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Reviva Pharmaceuticals Holdings stock, see the RVPH Stock Forecast page.
Spark’s Take on RVPH Stock
According to Spark, TipRanks’ AI Analyst, RVPH is a Underperform.
Reviva Pharmaceuticals Holdings faces significant financial challenges, with zero revenue, substantial net losses, and negative cash flows, heavily weighing down its stock score. The technical analysis indicates weak momentum and a downward trend, while the negative P/E ratio and lack of dividends reflect poor valuation. Recent corporate events show leadership confidence but do not mitigate the underlying financial distress.
To see Spark’s full report on RVPH stock, click here.
More about Reviva Pharmaceuticals Holdings
Average Trading Volume: 3,568,251
Technical Sentiment Signal: Sell
Current Market Cap: $28.35M
For an in-depth examination of RVPH stock, go to TipRanks’ Overview page.